Frank G Gilliam1,2, Kevin J Black3, Jewell Carter3, Kenneth E Freedland3, Yvette I Sheline4, Wei-Yann Tsai5, Patrick J Lustman3,6. 1. Department of Neuroscience, University of Kentucky, Lexington, KY. 2. Epilepsy Research Center, University of Kentucky, Lexington, KY. 3. Department of Psychiatry, Washington University, St Louis, MO. 4. Department of Psychiatry, University of Pennsylvania, Philadelphia, PA. 5. Department of Biostatistics, Columbia University, New York, NY. 6. Veterans Affairs St Louis Health Center, St Louis, MO.
Abstract
OBJECTIVE: Limited evidence is available to guide treatment of depression for persons with epilepsy. We evaluated the comparative effectiveness of sertraline and cognitive behavior therapy (CBT) for depression, quality of life, seizures, and adverse treatment effects. METHODS: We randomly assigned 140 adult outpatients with epilepsy and current major depressive disorder tosertraline or weekly CBT for 16 weeks. The primary outcome was remission from depression based on the Mini International Neuropsychiatric Interview (MINI). Secondary outcomes included the Quality of Life in Epilepsy Inventory-89 (QOLIE-89) seizure rates, the Adverse Events Profile (AEP), the Beck Depression Inventory, and MINI Suicide Risk Module. RESULTS: In the intention-to-treat analysis, 38 (52.8%; 95% confidence interval [CI] = ±12) of the 72 subjects assigned to sertraline and 41 (60.3%; 95% CI = ±11.6) of the 68 subjects in the CBT group achieved remission; the lower bound of efficacy for both groups was greater than our historical placebo control group upper bound of 33.7%. Difference in time to remission between groups was 2.8 days (95% CI = ±0.43; p = 0.79). The percent improvement of mean QOLIE-89 scores was significant for both the CBT (25.7%; p < 0.001) and sertraline (28.3%; p < 0.001) groups. The difference in occurrence of generalized tonic-clonic seizures between groups was 0.3% (95% CI = ±8.6; p = 0.95). Suicide risk at final assessment was associated with persistent depression (p < 0.0001) but not seizures or sertraline. INTERPRETATION: Depression remitted in just over one-half of subjects following sertraline or CBT. Despite the complex psychosocial disability associated with epilepsy, improving depression benefits quality of life. Serotonin reuptake inhibition does not appear to increase seizures or suicidality in persons with epilepsy. ANN NEUROL 2019;86:552-560.
RCT Entities:
OBJECTIVE: Limited evidence is available to guide treatment of depression for persons with epilepsy. We evaluated the comparative effectiveness of sertraline and cognitive behavior therapy (CBT) for depression, quality of life, seizures, and adverse treatment effects. METHODS: We randomly assigned 140 adult outpatients with epilepsy and current major depressive disorder to sertraline or weekly CBT for 16 weeks. The primary outcome was remission from depression based on the Mini International Neuropsychiatric Interview (MINI). Secondary outcomes included the Quality of Life in Epilepsy Inventory-89 (QOLIE-89) seizure rates, the Adverse Events Profile (AEP), the Beck Depression Inventory, and MINI Suicide Risk Module. RESULTS: In the intention-to-treat analysis, 38 (52.8%; 95% confidence interval [CI] = ±12) of the 72 subjects assigned to sertraline and 41 (60.3%; 95% CI = ±11.6) of the 68 subjects in the CBT group achieved remission; the lower bound of efficacy for both groups was greater than our historical placebo control group upper bound of 33.7%. Difference in time to remission between groups was 2.8 days (95% CI = ±0.43; p = 0.79). The percent improvement of mean QOLIE-89 scores was significant for both the CBT (25.7%; p < 0.001) and sertraline (28.3%; p < 0.001) groups. The difference in occurrence of generalized tonic-clonic seizures between groups was 0.3% (95% CI = ±8.6; p = 0.95). Suicide risk at final assessment was associated with persistent depression (p < 0.0001) but not seizures or sertraline. INTERPRETATION:Depression remitted in just over one-half of subjects following sertraline or CBT. Despite the complex psychosocial disability associated with epilepsy, improving depression benefits quality of life. Serotonin reuptake inhibition does not appear to increase seizures or suicidality in persons with epilepsy. ANN NEUROL 2019;86:552-560.
Authors: Robert S Fisher; J Helen Cross; Jacqueline A French; Norimichi Higurashi; Edouard Hirsch; Floor E Jansen; Lieven Lagae; Solomon L Moshé; Jukka Peltola; Eliane Roulet Perez; Ingrid E Scheffer; Sameer M Zuberi Journal: Epilepsia Date: 2017-03-08 Impact factor: 5.864
Authors: Jana E Jones; Bruce P Hermann; John J Barry; Frank Gilliam; Andres M Kanner; Kimford J Meador Journal: J Neuropsychiatry Clin Neurosci Date: 2005 Impact factor: 2.198
Authors: David W Loring; Daniel H Lowenstein; Nicholas M Barbaro; Brandy E Fureman; Joanne Odenkirchen; Margaret P Jacobs; Joan K Austin; Dennis J Dlugos; Jacqueline A French; William Davis Gaillard; Bruce P Hermann; Dale C Hesdorffer; Steven N Roper; Anne C Van Cott; Stacie Grinnon; Alexandra Stout Journal: Epilepsia Date: 2011-03-22 Impact factor: 5.864
Authors: Rosemarie Kobau; Hatice Zahran; David J Thurman; Matthew M Zack; Thomas R Henry; Steven C Schachter; Patricia H Price Journal: MMWR Surveill Summ Date: 2008-08-08
Authors: Heidi M Munger Clary; Rachel D Croxton; Jonathan Allan; James Lovato; Gretchen Brenes; Beverly M Snively; Mingyu Wan; James Kimball; Matthew H Wong; Cormac A O'Donovan; Kelly Conner; Victor Jones; Pamela Duncan Journal: Epilepsy Behav Date: 2020-01-27 Impact factor: 2.937
Authors: Rosa Michaelis; Venus Tang; Sarah J Nevitt; Janelle L Wagner; Avani C Modi; William Curt LaFrance; Laura H Goldstein; Milena Gandy; Rebecca Bresnahan; Kette Valente; Kirsten A Donald; Markus Reuber Journal: Cochrane Database Syst Rev Date: 2020-09-07
Authors: Heidi M Munger Clary; Rachel D Croxton; Beverly M Snively; Gretchen A Brenes; James Lovato; Fatemeh Sadeghifar; James Kimball; Cormac O'Donovan; Kelly Conner; Esther Kim; Jonathan Allan; Pamela Duncan Journal: Epilepsy Behav Date: 2020-11-24 Impact factor: 2.937